Ms. Wu Guangmei, Chairman of Beimei Pharmaceuticals, was appointed by the Global Association of Scientific and Technological Services in Shanghai on June 17, 2019.

The lecture on how to improve the cost-effectiveness of R & D was delivered at the Summit Forum on the development plan of 100 pharmaceutical enterprises.

In her speech, Wu pointed out that in the fully competitive Chinese pharmaceutical market, the most core competitiveness of pharmaceutical enterprises are mainly two aspects: marketing capabilities, research and development capabilities. The R & D capability provides the source power for the medium and long term development of the enterprise. Not only do innovative pharmaceutical companies need R & D capabilities, but generic drug companies also need R & D capabilities. In today's external environment has changed dramatically, how to improve the efficiency and cost-effectiveness of research and development is particularly important. In the new situation, to improve the cost-effectiveness of R & D, pharmaceutical enterprises need to pay attention to the following aspects of core competitiveness: selecting the right products, doing well in R & D strategies, strengthening project management.

With the view of globalization, integrating the latest technology and gathering the wisdom of Big names, this forum is committed to constructing a high-quality international communication platform between international capital market and Chinese pharmaceutical enterprises and intelligent manufacturing service providers.

As a new pediatric pharmaceutical company, Beimei has shown its corporate image to its peers at home and abroad, and on the other hand, it has benefited a lot from learning valuable experiences from many excellent enterprises through the platform.